PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2129048
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2129048
Cell Processing Instruments Market size was valued at US$ 7,051.6 Million in 2025, expanding at a CAGR of 7.3% from 2026 to 2033.
The cell processing equipment market refers to automated and semi-automated analytical tools for cell processing, including preparation, isolation, enumeration, characterization, imaging, and cell manipulation. These include cell processors, cell counters, flow cytometers, imaging equipment, and cell separators. Market trends are evolving from standalone measurements to combined processes for sample preparation, analysis, and process control. Cell and gene therapy manufacturing favors standardization, closed processing, and scalable quality controls. Therefore, competition among suppliers includes automation, throughput, integration of data, and compatibility with controlled processes. The 10-200 L capacity provided by Sartorius is indicative of the scaling requirements. Thus, market evolution is towards systems that reduce variability by the operator while preserving analytical and process control.
Cell Processing Instruments Market- Market Dynamics
Expansion of Cell and Gene Therapy Development Pipelines
The rise in cell and gene therapy research and development pipelines raises the need for more reproducible cell processing techniques such as handling, counting, enumeration, separation, and characterization. In an analysis performed in 2025, there were 4,418 therapies that included gene, cell, and RNA therapies in clinical and preclinical development as of March 31. There were 2,154 gene therapies, 966 non-genetically engineered cell therapies, and 1,298 RNA therapies among these 4,418 therapies. This means that approximately 48.8% were gene therapies in these pipelines, while non-genetically engineered cell therapies and RNA therapies comprised 21.9% and 29.4%, respectively. Therefore, the scope of these therapies indicates that diversity in applications will be an important demand driver for future integrated cell processing instruments.
The Global Cell Processing Instruments Market is segmented on the basis of Product Type, Application, End User, and Region.
By product type, product differentiation depends on workflow needs and processing complexity rather than the instrument category. The need for closed and reproducible processing becomes especially important for automated cell processing systems; cell counters allow for cell concentration and viability analysis; flow cytometers can provide multiparameter phenotyping; imaging systems provide morphological information; and separation systems assist with enrichment or depletion prior to subsequent processing. Sartorius positions Ksep systems for the automation of cell washing, concentration, and buffer exchanges for 10 L to 200 L processing scale, with a 20x scale range between the mentioned minimum and maximum processing scales. The BD FACSDiscover A8, introduced in 2025, allows for additional analytical possibilities based on spectral and real-time imaging and characterization of 50 or more cellular characteristics. Thus, scalability and analytical depth have become major factors in choosing the products. Consequently, competition in the products depends on automation, processing range, parameter density, and multimodality of the instrument rather than just availability.
By application, application priorities depend on the measurement and manipulation of cells impact decisions related to experiments, treatments, or manufacturing. Cell viability and proliferation workflows require fast measurements to assess the quality of cell culture, while isolation and separation workflows emphasize recovery, purity, and reproducible processing. Imaging and counting allow for not only the quantification of cells but also morphological characterization. The introduction of the BD FACSDiscover A8 in 2025 illustrates how measurement and manipulation have converged, as well as how the combination of spectral and real-time analysis can be used to characterize 50 or more cellular characteristics in a single analytical instrument. Automating cell separation also helps ensure process consistency in cell therapy workflows. The combination of at least 50 cellular characteristics in a single analytical instrument shows the direction toward high-content applications.
Cell Processing Instruments Market- Geographical Insights
North America, under the leadership of the United States, is a major demand center owing to the development of cell therapy, translational research, and manufacturing, leading to needs across discovery, process development, and quality control levels. According to FDA, 38 cellular and gene therapy products have been approved as of December 31, 2025, creating an established pool of products for which standardized cell processing and characterization can be carried out. The FACSDiscover A8 instrument, which has spectral and imaging capability, was commercially introduced by BD in 2025. The US includes manufacturers of instruments, biotech companies, biopharmaceutical developers, academic institutions, and regulations. The 38 approved products and the availability of platforms capable of analyzing 50 or more cellular parameters indicate a propelling market for cell-processing technologies with automation and high-parameter analysis.
Europe remains a significant region in terms of cell-processing instruments due to its large research capacity, biopharmaceutical manufacturing capabilities, and coherent life sciences policy on advanced cell processing. Specifically, the Life Sciences Strategy of the European Commission, introduced in July 2025, contains 27 actions related to competitiveness, research and innovation, skills, and regulation in the area of advanced cell processing and analysis. Moreover, Europe has a large research network of more than 1,500 universities and higher education institutions across the continent that contribute to the development of science and biotechnology. Additionally, Europe consists of 27 EU member states, providing a wide regulatory and commercial context for life science technologies. Sartorius improved its international operations throughout 2025 and undertook actions in France, Germany, and South Korea, among other countries. Twenty-seven EU member states, 27 strategic actions, and more than 1,500 higher education institutions reveal the significance of Europe's research and innovation network.
The competition is focused around diversified life science technology companies that combine instrumentation with software, reagents, consumables, automation, and process technologies. BD stands out with its unique offerings in high-parameter flow cytometry, spectral analysis, real-time imaging, and applications, whereas Sartorius offers technology solutions ranging from cell preparation to cell therapy workflows. Sartorius employed 14,042 people worldwide in 2025, indicating the scale of the company's organization that allows it to offer such a diverse technology portfolio. BD released its A8 technology platform commercially in May 2025; it added capabilities of spectral and imaging analysis, but further development in configurations allowed for broader applications in academia, pharmaceuticals, and biotechnology laboratories.
In May 2025, BD introduced the FACSDiscover A8 Cell Analyzer to its commercial market. This analyzer is equipped with spectral and live image technology. The technology allows for analyzing up to 50 parameters of the cell.
In December 2025, BD entered into a partnership with the Institute for Immunology and Immune Health at the University of Pennsylvania to develop deep immune profiling via flow cytometry. It is expected that the research will be conducted on 1,000 people.